Richard S. Finn
理查德·芬恩
MD
Professor of Medicine and Director, GI Oncology医学教授暨消化道肿瘤科主任
👥Biography 个人简介
Richard Finn is a world-renowned HCC trialist who led the IMbrave150 trial establishing atezolizumab plus bevacizumab as the new first-line standard for advanced HCC and co-led the REFLECT trial for lenvatinib. His work has fundamentally transformed the HCC therapeutic landscape.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
IMbrave150 Trial
Led the landmark IMbrave150 trial establishing atezolizumab plus bevacizumab as first-line standard for advanced HCC, replacing sorafenib after a decade.
REFLECT Trial Leadership
Co-led the REFLECT trial validating lenvatinib non-inferiority to sorafenib, broadening first-line treatment options in advanced HCC.
HCC Combination Immunotherapy
Pioneered investigation of immunotherapy-based combination regimens in HCC, informing a new era of checkpoint inhibitor plus anti-VEGF strategies.
Representative Works 代表性著作
Atezolizumab plus bevacizumab in unresectable HCC (IMbrave150)
New England Journal of Medicine (2020)
Practice-defining RCT establishing immunotherapy combination as first-line HCC standard, improving OS and PFS over sorafenib.
Lenvatinib versus sorafenib in first-line treatment of HCC (REFLECT)
The Lancet (2018)
Phase III non-inferiority trial that expanded first-line treatment options and showed superior ORR with lenvatinib.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Zev Wainberg
UCLA Health / David Geffen School of Medicine
Cathy Eng
Vanderbilt-Ingram Cancer Center
Daniel Coit
Memorial Sloan Kettering Cancer Center
Johanna Bendell
Sarah Cannon Research Institute
关注 理查德·芬恩 的研究动态
Follow Richard S. Finn's research updates
留下邮箱，当我们发布与 Richard S. Finn（UCLA David Geffen School of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment